# Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)

> **NCT02652780** · PHASE3 · COMPLETED · sponsor: **GenSight Biologics** · enrollment: 37 (actual)

## Conditions studied

- Optic, Atrophy, Hereditary, Leber

## Interventions

- **BIOLOGICAL:** GS010
- **DEVICE:** Sham Intravitreal Injection

## Key facts

- **NCT ID:** NCT02652780
- **Lead sponsor:** GenSight Biologics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2018-01
- **Final completion:** 2018-12
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02652780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02652780, "Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02652780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*